Anlotinib, a tyrosine kinase inhibitor, has been shown to exert an anti-cancer effect in vitro on KRAS mutant lung cancer cells by inhibiting the MEK/ERK pathway [79]. The gene discussed is KRAS; the disease is lung cancer.